Synergistic anticancer effects of camptothecin and sotorasib in <i>KRAS</i>-mutated pancreatic ductal adenocarcinoma.

ABSTRACT:

Background

Sotorasib (AMG510) is a first-in-class irreversible, covalent, and selective KRAS G12C inhibitor. However, in patients, acquired clinical resistance was observed within 1 year of its FDA approval. Researchers are exploring combination and repurposing strategies to help overcome this resistance and improve therapeutic efficacy. Several natural compounds have been extensively investigated for their therapeutic potential against various cancers, both individually and in combination with other chemotherapeutic agents. In this study, we examined the synergistic potential of camptothecin and sotorasib in KRAS G12C-mutated MIA PaCa-2 and KRAS G12D-mutated PANC-1 pancreatic ductal adenocarcinoma (PDAC) cells.

Methods

We assessed the half maximal inhibitory concentration (

SUBMITTER: Ramalingam PS 

PROVIDER: S-EPMC12314289 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature